# Alan Crane

> Alan Crane is a Series A investor at Polaris Partners backing Biotechnology and Health Care. See 19 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Polaris Partners](https://shizune.co/investors/profile/polaris-partners)
- Location: Cambridge, United States
- Total investments: 19
- Last investment: Oct 2025
- Lead investor: 21%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/alan-crane/0/911/b46

Alan Crane is a Series A investor at Polaris Partners in Cambridge focused on Biotechnology and Health Care. Alan Crane

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 11 | 58% |
| Health Care | 7 | 37% |
| Medical | 6 | 32% |
| Biopharma | 2 | 11% |
| Life Science | 2 | 11% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 37% |
| Series B | 5 | 26% |
| Series C | 3 | 16% |
| Seed | 1 | 5% |
| Series D | 1 | 5% |

7 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Zag Bio | Zag Bio™ has discovered a novel approach to create thymus-targeted medicines to treat and prevent autoimmune diseases by restoring central immune tolerance. Zag Bio designs bifunctional antibodies that deliver self-antigens to antigen-presenting cells in the thymus to harness the body’s natural process for training immune cells to recognize andtolerate self, halting or preventing autoimmune attacks on the body’s own tissues. Zag Bio’s pipeline includes ZAG-101, its lead program for Type 1 diabetes, as well as discovery programs for thymus-targeted therapies to address other autoimmune diseases and help patients and their caregivers. Located in Cambridge, Massachusetts, Zag Bio’s team includes experienced experts in thymus biology, autoimmune diseases and innovative drug development.Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases. | $80M | Series A | Oct 28, 2025 |  |
| Tome Biosciences | Tome Biosciences is a biotechnology company that develops programmable gene insertion technology. Using CRISPR, its technologies allow them to insert any genetic sequence of any size at any location into any genome. | $213M | Series A | Dec 12, 2023 |  |
| Seismic Therapeutic | Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements ofbiologics drug discovery – structural biology, protein engineering, and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to address adaptive immune system dysregulation to treat autoimmune diseases. | $121M | Series B | Dec 04, 2023 |  |
| Seismic Therapeutic | Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements ofbiologics drug discovery – structural biology, protein engineering, and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to address adaptive immune system dysregulation to treat autoimmune diseases. | $101M | Series A | Feb 09, 2022 |  |
| Dyno Therapeutics | Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for genetherapies. | $100M | Series A | May 06, 2021 |  |
| Dyno Therapeutics | Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for genetherapies. | $9M | Seed | May 11, 2020 |  |
| Pandion Therapeutics | Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants.Pandion’s approach has the potential to more effectively induce and sustainresponse and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety. | $58M | Series A | Jan 17, 2018 |  |
| YourBio Health | YourBio Health is developing novel products to optimize the interface of diagnostic medicine and the healthcare consumer by dramatically simplifying blood sampling and testing. By eliminating the barriers to the acquisition of critical diagnostic information, Seventh Sense is contributing to the future of informed, effective healthcare delivery andpatient participation in their own well-being. The Seventh Sense On Vivo™ platform will enable diagnostic testing to be performed safely and painlessly by virtually anyone, anywhere. Their proprietary, single-step Touch Activated Phlebotomy™ (TAP™) technology can be combined with a variety of diagnostic assays for rapid results. TAP's revolutionary sampling capabilities may also integrate with analytical systems to vastly improve the patient and clinician experience. | $10M | Series C | Nov 18, 2016 |  |
| Navitor Pharmaceuticals | Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTORpathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases.It was founded in 2009 and headquartered in Cambridge, Massachusetts. | $33M | Series B | Dec 18, 2015 |  |
| YourBio Health | YourBio Health is developing novel products to optimize the interface of diagnostic medicine and the healthcare consumer by dramatically simplifying blood sampling and testing. By eliminating the barriers to the acquisition of critical diagnostic information, Seventh Sense is contributing to the future of informed, effective healthcare delivery andpatient participation in their own well-being. The Seventh Sense On Vivo™ platform will enable diagnostic testing to be performed safely and painlessly by virtually anyone, anywhere. Their proprietary, single-step Touch Activated Phlebotomy™ (TAP™) technology can be combined with a variety of diagnostic assays for rapid results. TAP's revolutionary sampling capabilities may also integrate with analytical systems to vastly improve the patient and clinician experience. | $16M | Series B | Aug 13, 2014 |  |

10 of 19 investments shown.

## Co-investors
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 6 deals together
- [Flagship Pioneering](https://shizune.co/investors/profile/flagship-ventures) — VC Fund, 5 deals together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 3 deals together
- [Lightspeed Venture Partners](https://shizune.co/investors/profile/lightspeed-venture-partners) — VC Fund, 3 deals together
- [Lux Capital](https://shizune.co/investors/profile/lux-capital) — VC Fund, 3 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 3 deals together

## About Polaris Partners

VC Fund · Boston, United States

Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.

5 contacts available at Polaris Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Isaac Ciechanover | Partner | https://shizune.co/investors/profile/isaac-ciechanover |
| Sharif Vakili | Associate | https://shizune.co/investors/profile/sharif-vakili |
| Alan Crane | Partner and Entrepreneur | https://shizune.co/investors/profile/alan-crane |
| Alexandra Cantley | Partner | https://shizune.co/investors/profile/alexandra-cantley-1374 |
| Amir Nashat | Managing Partner | https://shizune.co/investors/profile/amir-nashat |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Alan Crane invest in?

Alan Crane invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Alan Crane last invest?

The most recent investment recorded for Alan Crane closed in Oct 2025. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co